Medera Inc. ('Medera'), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction (MI) and preserved left ventricular ejection fraction (LVEF) found this ...

A recent study revealed a high prevalence of stage B heart failure (HF) in a general clinical setting in India. The authors ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

In this issue of the journal, Shoji et al showed that isolated non-specific ST-segment and T-wave abnormalities (NSSTTAs) are associated with incident heart failure (HF).1 The authors conducted a ...

Edgewise Therapeutics (EWTX) stock rises as the company updates mid-stage trial results for EDG-7500, its test drug for hypertrophic cardiomyopathy. Read more here.

In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...

When Anthony Guacci walked into Atrium Health Carolinas Medical Center last fall, he had no idea how close he was to the end ...

Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...

Investing.com -- Edgewise Therapeutics Inc (NASDAQ:EWTX) stock rose 4.8% in premarket trading Wednesday after the company announced positive updates from its ongoing Phase 2 clinical trial of EDG-7500 ...

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...